MSF TB Project |  Amudarya rayon (district), Karakalapakstan
In Karakalpakstan, western Uzbekistan, we focus on the implementation of a comprehensive care programme for drug-resistant and drug-sensitive tuberculosis (TB).

With the comprehensive care programme, we support the Ministry of Health (MoH) in its rollout of protocols reflecting global best practices, as well as introduce healthcare innovations, and promote shorter course TB treatment regimens using new and repurposed drugs. 

We have also implemented the TB PRACTECAL clinical trial. This is the first-ever multi-country, randomised, controlled clinical trial, aiming to demonstrate the safety and efficacy of a six-month, all oral treatment regimen for drug-resistant TB. We are now working with the World Health Organization to promote the new regimen as the international standard of care for drug-resistant TB patients.

In the capital, Tashkent, we provide support for the diagnosis and treatment of people living with HIV and co-infections. In 2021, we also launched a mobile laboratory to support the diagnosis of HIV and co-infections among vulnerable people. 

Our teams also support the MoH in its efforts to develop the public healthcare system.

Our activities in Uzbekistan in 2020

Data and information from the International Activity Report 2020.

MSF in Uzbekistan in 2020 In Uzbekistan, MSF works with the Ministry of Health to improve diagnostics and treatment for people with tuberculosis (TB), including drug-resistant forms of the disease, and provide HIV care.
Uzbekistan Activities 2020

In 2020, in collaboration with the health ministry, we updated the national protocol to support the use of an all-oral short-course TB regimen with bedaquiline as a core component. Bedaquiline is a highly effective drug that has been proven to improve outcomes for patients. The protocol now also includes a section on palliative care for TB patients who have limited therapeutic options.  

In our project in Karakalpakstan, we continued to roll out the latest evidence-based TB treatment guidelines across all 17 districts.

In September, we launched a new health promotion unit in Nukus, which will conduct awareness sessions in the community as well as health education and support groups for patients in TB facilities.

Meanwhile, we are continuing our multi-site clinical trial, TB PRACTECAL, at two sites in Nukus and Tashkent to develop radically improved treatment for people with multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).

During the global COVID-19 pandemic, we reinforced infection prevention and control measures in healthcare settings, and ensured continuity of care for our HIV and TB patients. Innovative practices such as Video Observed Treatment (VOT) and Family-Directly Observed Treatment (F-DOT), in which health workers or family members watch the patient take their drugs, played an important role in supporting patients to adhere to their treatment during the lockdown. We continue to strengthen outpatient models of care that are tailored to patients’ needs and requirements, and expect to roll out VOT and F-DOT further in 2021.

In 2020, MSF started cooperating with the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to implement the ‘one-stop shop’ model developed in Tashkent, in another region, Syrdarya. The ‘one-stop shop’ is a person-centred approach that allows people living with HIV to receive multidisciplinary care in the same location. This is the first time that such an approach has been proposed and implemented in Central Asia.  


in 2020

MSF cooks for people of Munyak on last day of the year

Project Update 30 Dec 1999

Stop the Aral Sea and its people from disappearing off the map

Press Release 20 Apr 1998